Search Results Page

Lupin and Cipla bring cheer

about 6 years ago

Cipla and Lupin are having a fantastic day on the bourses today. The stock price of Cipla surged almost 6.5% to Rs.799.80

Cipla in the spotlight

about 8 years ago

Cipla is in the spotlight today. The moment it opened, it rose 2% to Rs.592.15. The stock’s high and low is at Rs.663 and Rs.508.10 respectively.

Cipla posts a turnaround

about 9 years ago

Piggy-backing on good growth from India and South Africa, Cipla posted a turnaround performance for Q4FY18. From a net loss of Rs.62 crore in Q4FY17,

Cipla breathes easy!

about 9 years ago

Cipla rose 3.3% at Rs.612.55 and it remains firmly in the green. The stock’s 52-week high and low is at Rs.663 and Rs.479 respectively.

Cipla gets bitter pill from CLSA

about 10 years ago

Cipla actually posted a better set of numbers vis-à-vis Q4FY16. It remains in the red but its consolidated net loss of Q4FY17 came down to Rs.62 crore v/s Rs.93 crore (YoY)

Cipla shining bright

about 11 years ago

Cipla is shining like a bright star in this falling market. Up almost 3.5% at Rs.679.50, the stock is now barely managing to hold on to the green. Its 52-week high and low stands at Rs.752.45 and Rs.546 respectively. The company announced today morning that Cipla (EU) Limited, U.K., the whol ...

Cipla gets 'FDA'ed

about 7 years ago

When any pharma stock falls, it is almost always the FDA at the crux. And that’s exactly the reason why Cipla opened today with a loss of almost 5.5%

Cipla hits new low

about 7 years ago

Cipla went down 5% to hit a new 52-week low at Rs.418 today. It has come off the low but remains firmly in the red at 425 levels.

Cipla stuns with poor Q2

about 8 years ago

Cipla stunned everyone with a very disappointing set of earnings for Q2FY19. While the company has blamed it all the higher base of last year due to GST restocking

Cipla rises almost 8%

about 9 years ago

Cipla had a good run on the BSE today. The stock price rose almost 8% to Rs.613. Its 52-week high is at Rs.663.

Cipla gets 'FDA'ed

about 7 years ago

Cipla is not doing too well today. The stock had closed yesterday at Rs.451.50, and it opened weaker at Rs.447, going down to an intraday low at Rs.435.60

Cipla turns sweet

about 7 years ago

Cipla is up in the green today morning as the market is happy with its recent purchase of an anti-diabetic trademark and brand.

Cipla on a wonderful run

about 12 years ago

Cipla has been on a wonderful run on the bourses for the past few days. It has been hitting a new high consistently for the past three consecutive days. Today’s new high stands at Rs.746.50. The company yesterday announced that Stempeutics Research, a group company of Manipal Educ ...

Cipla in the green

about 5 years ago

The stock is up in the green today, rising over 2.5% to an intraday high at Rs.927.85 on the back of 1.5 times rise in volumes. Its 52-week high is at Rs.966.

Cipla in pink of health

about 11 years ago

Cipla announced a set of bumper numbers for Q1FY16, exceeding all expectations. But yet, the stock has tanked, figuring out amongst the top losers currently. The stock is down over 4% at Rs.711 but it seems to have recouped from its low point of Rs.703. Profit booking and worry over its cautious ...

Cipla rises 5%

about 6 years ago

The stock reacted positively to this news, opening 2% higher at Rs.772 and rising 5% to Rs.792.80. Its 52-week high is at Rs.829.

Cipla continues to rise

about 12 years ago

Cipla continues to do well even today. The stock which closed in the green yesterday at Rs.618.60, opened higher today at Rs.625, which was actually its days lowest, going on to hit the intra day high at Rs.645. It is currently ruling around Rs.635 levels, up 3%. The stock continues to react ...

Cipla spikes up on 'Sri Lankan' pill

about 13 years ago

Cipla is currently the top gainer on the BSE, up over 5.6% at Rs.435.75, with an intra day high at Rs.443.20. Volumes have shot up over 2.4 times. Its 52-week high stands at Rs.450. The stock is in the limelight, reacting today to the news which it announced yesterday afternoon during market ...

Cipla hits a new high

about 5 years ago

From its yesterday’s close of Rs.979, the stock opened 1.5% higher at Rs.994 and went on to hit a new 52-week high at Rs.997.20.

Cipla treated well

about 5 years ago

The stock is is currently the top gainer on the BSE, opening over 0.5% higher at Rs.865.95 and rising 2.5% to hit an intraday high at Rs.881.05.

Cipla tumbles down

about 5 years ago

The stock opened 4% lower at Rs.916.70 and went down to an intraday low at Rs.910.05, a decline of over 4.5%. Volumes show an extraordinary jump

Cipla breathes easy

about 7 years ago

The stock is the top gainer on the BSE, jumping up to an intraday high at Rs.447.95, surging almost 8.5%.

Cipla breathes easy

about 7 years ago

The stock opened with a gain of 10% at Rs.564.30 and rose to an intraday high at Rs.595, a jump up of 16% and a new 52-week high.

Cipla looks healthy

about 7 years ago

The stock is currently the top gainer on the BSE, rising 4.5% to Rs.615.15. Its 52-week high is at Rs.632 and today’s 10% UC

Cipla looks healthy

about 7 years ago

The stock, which had closed on Friday at Rs.570.20, opened almost flat at Rs.570.45 but from there, jumped to an intraday high at Rs.593.60.

Cipla at new high

about 6 years ago

The stock price rose over 9% in the morning trades to hit an intraday high at Rs.696, which is also a new 52-week high

Cipla inhales big and high

about 12 years ago

Cipla is the top gainer on the BSE currently, up almost 7% at Rs.566, with an intyra day high at Rs.575.20, a new 52-week high. Volumes have surged 2.15 times. The stock is reacting positively to the news of its launch of Serroflo, its top asthma drug in Sweden and Germany. This is the gener ...

Cipla brings cheer

about 6 years ago

The stock is in the green; from its close of Rs.634.45, the stock opened at Rs.645.20, which is its intraday high. It is currently come off the high and is trading at Rs.638 levels.

Cipla jumps over 3% on FDA nod

about 8 years ago

Cipla, in the opening bell session rose almost 3.5% to Rs.622 but profit booking came in at this level and it is now at Rs.612 levels, up around 2%.

Cipla remains volatile

about 6 years ago

The stock, which had closed yesterday at Rs.888.70, rose over 3% to Rs.916.50 and then went down into the red at Rs.885.10 and is now back in the black at Rs.892

Cipla leaves a very bitter taste

about 11 years ago

Cipla hit a new 52-week low today at Rs.458.25 on the back of its poor show for Q4Fy16. The numbers were very disappointing as most analysts had expected an increase in the bottomline. The company reported a very sharp 69% (YoY) fall in net profit for Q4FY16 at Rs.81 crore though income from ...

Cipla loses on disappointing Q3

about 13 years ago

Cipla is a big loser currently, down 4.3% at Rs.395, with a low at Rs.390 and volumes have spiked up 1.2 times. The stock is down in the red after its net profit for Q3FY14 fell 23% (YoY) at Rs.261 crore though net sales showed a growth of 10% at Rs.2281 crore. EBITDA was down 18% at Rs.403 ...

Cipla jumps over 9%

about 3 years ago

The stock is among the top five gainers on the BSE currently; opening 4% higher at Rs.1112, it zoomed to an intraday high at Rs.1169.35, rising 9.5%.

Cipla down in the red

about 3 years ago

The stock opened almost 1% lower at Rs.1232.65 and went down to an intraday low at Rs.1226.40, down almost 1.5%.

Cipla up 10%

about 2 years ago

Figuring among the top three gainers on the BSE, the stock opened over 7% higher and soon rose to an intraday high at Rs.1557.45, up 10%. Its 52-week high stands at Rs.1702.

Cipla back on "buy" list of FIIs

about 10 years ago

Cipla is trading with a lot of volume today, rising almost 2.5 times and the stock price rose over 2% to Rs.565 levels and is now trading at Rs.561. Bargain hunting is the watch word today on the bourses and here, it is helped by some favorable reports from foreign brokerage houses too. On S ...

Pharma companies sulk as prices go down

about 11 years ago

Abbott Healthcare, Lupin, Alembic, Alkem Labs, Novartis and many more such pharma companies are trading in the red. Cipla and Sun are just about holding onto the green. It is always seen, what is good for the peopleis not good for the market. If prices are reduced, the markets sulk while peo ...

Pharma stocks in reckoning

about 4 months ago

The rally was broad-based, with Dr. Reddy’s gaining up to 2.6%, Cipla nearly 3%, Laurus Labs over 3%, Zydus Lifesciences around 2.8%, Sun Pharma over 1.5%, while Piramal Pharma surged more than 8% on the supply-opportunity trigger.

Pharma and 'Labs' rule today

about 5 years ago

Cipla is the top gainer, up over 7% currently at Rs.964, followed by Dr.Reddy’s, Aurobindo Pharma, Divis Labs, Lupin, Torrent Pharma. Diagnostic stocks – Lalpath Labs, Metropolis, Vijaya Diagnostics,

Pharma stocks get beaten down

about 12 years ago

The top four losers amongst the five on the BSE are all pharma stocks. This was the every same sector which was the toast of the street, even till yesterday but today, the tide has suddenly turned. The top loser is Torrent Pharma, down over 3%, Lupin is down 3%, Sun Pharma Advanced Research is do ...

POLITICIANS BECOMING INDUSTRIALISTS - WHATS WRONG IN THAT?

about 10 years ago

Is there something wrong if industrialists become politicians? Jindal? Or even Nandan Nilekani. Yes, politics is dirty and the current entire clan of politicians looks like a band of bandits. So if today we have a credible and very able person wanting to lead as a politician, isn't that good new

IT'S ALL IN THE FAMILY!

about 10 years ago

A couple of days ago, China's richest man, Wang Jianlin, 62, founder and chairman of Dalian Wanda Group Co, owning a $92 billion empire announced that his only son, the heir apparent to his wealth, was no interested in taking over the business. This has prompted Wang to look for a successor

Emcure Pharma

about 2 years ago

Naam Bade aur Darshan Chote
Subscription Start Date :3 Jul 2024 End Date :5 Jul 2024
Issue Size : Rs. 1,952 cr, Issue Type : Fresh cum OFS
Price Band : Rs.960 to Rs. 1008
--------------------------------------------------
Overall Subscription : 67.87x
QIB : 195.83x,HNI :48.32x,Retail :7.21x,Other :8.81x
Listing Date : 10 Jul 2024, , Listing Price : 1325

IMPAIRMENT – TO BECOME COMMON OCCURENCE

about 6 years ago

Impairment hits were far and few in between. But in Q4FY20, we see that this has become a norm with more and more companies going the impairment route due to the pandemic.

Q4FY18 – A MIXED BAG OF SOUR AND SWEET

about 9 years ago

This week marks the beginning of the earning season for Q4FY18. Q2 and Q3 were pretty stable, what with the disruption of demon and GST earlier. And now we have Q4 where there is murmur of more weakness that strength in the numbers.

INDIA'S 'PHOREN' SHOPPING SPREE - KEEP THE BILL SMALL!

about 11 years ago

2006. Oh we all felt so proud! The largest acquisition ever in this world and that label belonged to an Indian company. Tata Steel buying Corus. The price tag was unheard of - a staggering $13.6 billion. We all knew it meant that this would leverage the balance sheet of Tata Steel to the hilt. But we could not be blamed then;

INDUSTRIALISTS AS POLITICAL LEADERS - WHY NOT?

about 11 years ago

KV Kamath has been appointed as the Chief of BRIC Bank and that was unanimously agreed by one and all that it was a great choice. And that leads us to the thought - why can't we have more industrialists join active politics and help lead the country through this current quick sand?

INDUSTRIALISTS AS POLITICAL LEADERS - WHY NOT?

about 13 years ago

There was such a big hullabaloo over news that Nandan Nilekani might join the Congress and get into active politics. What is wrong in that? Yes, politics is dirty and the current entire clan of politicians looks like a band of bandits. So if today we have a credible and very able person like Nandan Nilekani wanting to lead as a politician, isn't that good news?

RANBAXY - TO BUY OR NOT TO BUY?

about 14 years ago

Well, the stock price is up over 3% currently, with more buyers than sellers on the counter. Does this mean that the market does not care about this ruling? It surely does but for the market, more than the felony charges or the loss of reputation, the fact that the company has already provided for the $500 million and this might have any material impact now is what matters. It was happy that the case which

NOVARTIS CASE RULING - GOOD FOR INDIANS AND INDIAN COMPANIES

about 14 years ago

A storm was brewing on the Indian pharma sector and Novartis was in the eye of the storm. The much awaited verdict on Novartis anti-cancer drug, Glivec was announced by the Supreme Court today and it ruled against the company. This might not be good news for Novartis and the other big MNCs but for the people of India and the scores of domestic Indian pharma companies, especially Cipla, Dr.Reddy's, Auroboindo and Natco

YUSUF HAMIED - A MODERN DAY MESSIAH?

about 14 years ago

Mr.Hamied is rarely seen or heard but he has done and is doing remarkable things for the Indian pharma sector. Everyone makes or strives to make profits but Mr.Hamied's aim was to get drugs to the people at the most affordable cost. This, for someone who is essentially a

NOVARTIS CASE - IT'S THE FINAL COUNTDOWN

about 14 years ago

Currently a legal storm is brewing in the Indian pharma sector and in the eye of the storm is Novartis and if it wins the case it will mean two things - medicines will get costlier and companies will file for patents on frivolous grounds, making very minor changes in existing drugs and thereby establish or expand its monopolyon a drug.

Wockhardt bounces back

about 7 years ago

For a brief moment of time, Wockhardt notched the spot at the top gainer on the BSE, following its turnaround performance for Q3FY20.